Drugs / Trosunilimab
Trosunilimab
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06632938 | Oct 2024 → May 2025 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT04554966 | Apr 2021 → Aug 2023 | HIV infectious disease | AbbVie | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07697456 | Jul 2026 → Oct 2031 expected | Crohn disease, ulcerative colitis | AbbVie | Recruiting | No outcome recorded |
| Phase 2 | NCT06548542 | Sep 2024 → Jan 2030 expected | Crohn disease | AbbVie | Recruiting | No outcome recorded |
| Phase 2 | NCT06032546 | Oct 2023 → Sep 2025 | HIV infectious disease | AbbVie | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trosunilimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06548542 ↗ |
| Known as | ABBV-382 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04554966 ↗ |
| Known as | PR-1794842 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068185 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068185 ↗ |
| Route | Intravenous | “Intravenous (IV) infusion” NCT04554966 ↗ |